India Pharma Outlook Team | Tuesday, 25 November 2025
Alkem Laboratories Ltd has introduced DSS, the original De Simone formulation probiotic mixture in India, aimed at restoring gut microbiota equilibrium and addressing several gut-related health issues.
Created by Prof. Claudio De Simone, this exclusive probiotic incorporates eight meticulously chosen bacterial strains in exact ratios, selected for their unique biochemical and enzymatic characteristics, to work together on the functioning of the gastrointestinal system.
The De Simone formulation is acknowledged as one of the most thoroughly studied probiotics globally, supported by more than 80 clinical trials and 200 publications in the past twenty years.
Also Read: Roche Secures EU Nod for Lunsumio SC One-Minute Injection
It is also supported by prominent American and European gastroenterology organizations in their recommendations for treating gastrointestinal issues. Alkem has obtained the rights to these formulations from Next Gen Pharma India Pvt. Ltd. Alkem’s DSS lineup will be offered in four strengths – a 225 billion CFU sachet, a 112.5 billion CFU capsule, a 45 billion CFU capsule, and a 10 billion CFU capsule – giving healthcare professionals and patients customized choices to address a broad range of gastrointestinal issues.
Alkem is the initial firm in India to provide all four strengths of this probiotic and the first to introduce the 225 billion CFU and 10 billion CFU strengths in the country, for which it holds exclusive marketing rights. The DSS probiotic consists of eight live, freeze-dried bacterial species – four from lactobacillus, three from bifidobacterium, and one from streptococcus – which function to aid in restoring gut microbiota equilibrium and provide established clinical advantages.
DSS is recommended for treating several conditions including irritable bowel syndrome (IBS), ulcerative colitis (UC), pouchitis, hepatic encephalopathy (HE), non-alcoholic fatty liver disease (NAFLD), cirrhosis, bacterial vaginosis (BV), antibiotic-associated diarrhoea (AAD), and other disorders related to gut dysbiosis, along with use during pregnancy and breastfeeding.
